70 related articles for article (PubMed ID: 22921185)
1. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials.
Mahner S; Eulenburg C; Staehle A; Wegscheider K; Reuss A; Pujade-Lauraine E; Harter P; Ray-Coquard I; Pfisterer J; du Bois A
Eur J Cancer; 2013 Jan; 49(1):142-9. PubMed ID: 22921185
[TBL] [Abstract][Full Text] [Related]
2. Current status of maintenance therapy for advanced ovarian cancer.
Hope JM; Blank SV
Int J Womens Health; 2010 Aug; 1():173-80. PubMed ID: 21072286
[TBL] [Abstract][Full Text] [Related]
3. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).
Cardoso F; Costa A; Norton L; Senkus E; Aapro M; André F; Barrios CH; Bergh J; Biganzoli L; Blackwell KL; Cardoso MJ; Cufer T; El Saghir N; Fallowfield L; Fenech D; Francis P; Gelmon K; Giordano SH; Gligorov J; Goldhirsch A; Harbeck N; Houssami N; Hudis C; Kaufman B; Krop I; Kyriakides S; Lin UN; Mayer M; Merjaver SD; Nordström EB; Pagani O; Partridge A; Penault-Llorca F; Piccart MJ; Rugo H; Sledge G; Thomssen C; Van't Veer L; Vorobiof D; Vrieling C; West N; Xu B; Winer E; ;
Breast; 2014 Oct; 23(5):489-502. PubMed ID: 25244983
[No Abstract] [Full Text] [Related]
4. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†.
Cardoso F; Costa A; Norton L; Senkus E; Aapro M; André F; Barrios CH; Bergh J; Biganzoli L; Blackwell KL; Cardoso MJ; Cufer T; El Saghir N; Fallowfield L; Fenech D; Francis P; Gelmon K; Giordano SH; Gligorov J; Goldhirsch A; Harbeck N; Houssami N; Hudis C; Kaufman B; Krop I; Kyriakides S; Lin UN; Mayer M; Merjaver SD; Nordström EB; Pagani O; Partridge A; Penault-Llorca F; Piccart MJ; Rugo H; Sledge G; Thomssen C; Van't Veer L; Vorobiof D; Vrieling C; West N; Xu B; Winer E
Ann Oncol; 2014 Oct; 25(10):1871-1888. PubMed ID: 25234545
[No Abstract] [Full Text] [Related]
5. Incorporation of pazopanib in maintenance therapy of ovarian cancer.
du Bois A; Floquet A; Kim JW; Rau J; del Campo JM; Friedlander M; Pignata S; Fujiwara K; Vergote I; Colombo N; Mirza MR; Monk BJ; Kimmig R; Ray-Coquard I; Zang R; Diaz-Padilla I; Baumann KH; Mouret-Reynier MA; Kim JH; Kurzeder C; Lesoin A; Vasey P; Marth C; Canzler U; Scambia G; Shimada M; Calvert P; Pujade-Lauraine E; Kim BG; Herzog TJ; Mitrica I; Schade-Brittinger C; Wang Q; Crescenzo R; Harter P
J Clin Oncol; 2014 Oct; 32(30):3374-82. PubMed ID: 25225436
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.
Cameron D; Brown J; Dent R; Jackisch C; Mackey J; Pivot X; Steger GG; Suter TM; Toi M; Parmar M; Laeufle R; Im YH; Romieu G; Harvey V; Lipatov O; Pienkowski T; Cottu P; Chan A; Im SA; Hall PS; Bubuteishvili-Pacaud L; Henschel V; Deurloo RJ; Pallaud C; Bell R
Lancet Oncol; 2013 Sep; 14(10):933-42. PubMed ID: 23932548
[TBL] [Abstract][Full Text] [Related]
7. The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study.
Hofstetter G; Concin N; Braicu I; Chekerov R; Sehouli J; Cadron I; Van Gorp T; Trillsch F; Mahner S; Ulmer H; Grimm C; Castillo-Tong DC; Zeillinger R; Zeimet AG; Vergote I
Gynecol Oncol; 2013 Oct; 131(1):15-20. PubMed ID: 23877013
[TBL] [Abstract][Full Text] [Related]
8. Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer.
Timmermans M; van der Aa MA; Lalisang RI; Witteveen PO; Van de Vijver KK; Kruitwagen RF; Sonke GS
Gynecol Oncol; 2018 Sep; 150(3):446-450. PubMed ID: 30001834
[TBL] [Abstract][Full Text] [Related]
9. The impact of varying levels of residual disease following cytoreductive surgery on survival outcomes in patients with ovarian cancer: a meta-analysis.
Chase DM; Mahajan A; Scott DA; Hawkins N; Kalilani L
BMC Womens Health; 2024 Mar; 24(1):179. PubMed ID: 38491366
[TBL] [Abstract][Full Text] [Related]
10. Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients.
Farolfi A; Petracci E; Gurioli G; Tedaldi G; Casanova C; Arcangeli V; Amadori A; Rosati M; Stefanetti M; Burgio SL; Cursano MC; Lolli C; Zampiga V; Cangini I; Schepisi G; De Giorgi U
Front Oncol; 2023; 13():1221096. PubMed ID: 37664032
[TBL] [Abstract][Full Text] [Related]
11. Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: a systematic literature review.
Chase DM; Mahajan A; Scott DA; Hawkins N; Kalilani L
Int J Gynecol Cancer; 2023 Oct; 33(10):1602-1611. PubMed ID: 37643825
[TBL] [Abstract][Full Text] [Related]
12. Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer.
Andrikopoulou A; Theofanakis C; Markellos C; Kaparelou M; Koutsoukos K; Apostolidou K; Thomakos N; Haidopoulos D; Rodolakis A; Dimopoulos MA; Zagouri F; Liontos M
Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444629
[TBL] [Abstract][Full Text] [Related]
13. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics.
Anand U; Dey A; Chandel AKS; Sanyal R; Mishra A; Pandey DK; De Falco V; Upadhyay A; Kandimalla R; Chaudhary A; Dhanjal JK; Dewanjee S; Vallamkondu J; Pérez de la Lastra JM
Genes Dis; 2023 Jul; 10(4):1367-1401. PubMed ID: 37397557
[TBL] [Abstract][Full Text] [Related]
14. Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study.
Liu X; Zhao Y; Jiao X; Yu Y; Li R; Zeng S; Chi J; Ma G; Huo Y; Li M; Peng Z; Liu J; Zhou Q; Zou D; Wang L; Li Q; Wang J; Yao S; Chen Y; Ma D; Hu T; Gao Q
J Ovarian Res; 2023 Jun; 16(1):121. PubMed ID: 37370087
[TBL] [Abstract][Full Text] [Related]
15. An Asian Tertiary Centre's Early Experience with Laparoscopic Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis.
Le Linn Y; Seo CJ; Wong JSM; Ong CJ; Chia CS
Indian J Surg Oncol; 2023 Jun; 14(Suppl 1):175-180. PubMed ID: 37359940
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of Laparoscopic Optimal Interval Cytoreduction Surgery (LOICS) in Patients with Advanced Ovarian Cancers Having Low Burden Disease.
Gupta V; Rao T; Raju K; Iyer RR; Ahmed SM; Shah M; Nagaraju R
Indian J Surg Oncol; 2023 Mar; 14(1):270-276. PubMed ID: 36891449
[TBL] [Abstract][Full Text] [Related]
17. Survival Outcomes of Patients with International Federation of Gynecology and Obstetrics Stage IV Ovarian Cancer: Cytoreduction Still Matters.
Xiao Y; Linghu H
Cancer Control; 2023; 30():10732748231159778. PubMed ID: 36815671
[TBL] [Abstract][Full Text] [Related]
18. Laparoscopic Cytoreduction Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Peritoneal Surface Malignancies (PSM): Italian PSM Oncoteam Evidence and Literature Review.
Sommariva A; Valle M; Gelmini R; Tonello M; Carboni F; De Manzoni G; Sorrentino L; Pasqual EM; Bacchetti S; Sassaroli C; Di Giorgio A; Framarini M; Marrelli D; Casella F; Federici O
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612274
[TBL] [Abstract][Full Text] [Related]
19. Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis.
Bryant A; Johnson E; Grayling M; Hiu S; Elattar A; Gajjar K; Craig D; Vale L; Naik R
Am J Ther; 2023 Jan-Feb 01; 30(1):e36-e55. PubMed ID: 36608071
[TBL] [Abstract][Full Text] [Related]
20. Association between Serum Biomarkers with Postoperative Complications and Delay of Adjuvant Chemotherapy Initiation in Ovarian Cancer Patients Undergoing Primary Cytoreductive Surgery: A Pilot Study.
Ade CJ; Dockery L; Walter AC; Benbrook DM; Vesely SK; Hammond ST; Moore KN; Holman LL
Nutr Cancer; 2023; 75(2):662-669. PubMed ID: 36495155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
